Clinical trial
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
NCT00048295 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00048295 |
|---|---|
| Title | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease |
| Official title | ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Alicaforsen |
| Enrollment | 150 |
| Start date | May 1, 2002 |
| First posted | Oct 30, 2002 |
| Last update posted | Aug 15, 2022 |
| Countries | Belgium, Czechia, Germany, Italy, Poland, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: